Development and Validation of UV Spectrophotometric Method for Detection of Glibenclamide during Dissolution in Alkaline Borate Buffer pH 9.5
This article describes the development of UV spectrophotometric method for detection of glibenclamide during its dissolution in alkaline borate buffer pH 9.5 because no official UV spectrophotometric method is described for this drug and no such method has been developed for estimating the drug in this medium. A stock solution of 20 g/ml was prepared. Various aliquots of the stock solution were transferred to a series of 10 ml capacity volumetric flasks so as to prepare various dilutions between the ranges of 2-12 g/ml. To each dilution 0.1 ml of concentrated hydrochloric acid was added and a calibration curve was formed at 229.5 nm between absorbance on Y- axis and concentration on X- axis. The linearity range was found to be between 2.0 to 12.0 g/ml. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.23 g/ml and 0.71 g/ml respectively. The repeatability, interday and intraday precision (measured in terms of percent relative standard deviation, %RSD) was always less than 0.94%. The accuracy of the developed method were measured by recovery studies and was found to be between 100.39%±1.03% and 102.94%±1.46%. Thus, the developed method is specific, accurate and precise as validated according to recommendations by ICH guidelines.
2.Davis SN. (2006). Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: L. L. Brunton, J. S. Lezo, K. L. Parker (Eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Ed. (pp. 1634). New Delhi: McGraw Hill Publishing Division.
3.Anonymous. (1996). Glibenclamide. In: Indian Pharmacopoeia1996, 4th Ed. Vol. I. (pp. 347). New Delhi: The Indian Pharmacopoeia Commission, Central Indian Pharmacopoeia Laboratory, Govt. of India, Ministry of health & family welfare, Controller of publications.
4.FDA Dissolution methods, List of all drugs in the database, Glyburide. http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1 (Accessed on 17/06/2012)
5.Dressman JB, Lo¨benberg R, Kra¨mer J, Shah VP, Amidon GL. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharmaceutical Research. 2000; 17(4): 439-444.
6.Hindustan A A, Meghana M, Navya K, Mallika B, Aaslesha A, Srilatha V, Chitta SK. Designing and evaluation of glibenclamide azadirachta indica mucilage based controlled release matrix tablets. Der Pharmacia Lettre. 2010; 2(1): 117-121.
7.Gianotto EADS, Arentis RP, Lara-Filho MJ, Filho ACSC, Fregonezi-Neri MM. Dissolution test for glibenclamide tablets. Quim. Nova. 2007; 30(5): 1218-1221.
8.Davidson AG. (1997). UV-Visible spectrophotometry. In: Backett AH, Stenlake JB (Eds) Practical pharmaceutical chemistry, Part 2, 4th Ed., 1st Indian Ed. (pp. 309). New Delhi: CBS Publishers and Distributors Pvt. Ltd.
9.ICH Guidelines Q2(R1). Validation of analytical procedures: text and methodology. ICH Harmonised Tripartite Guidelines, adopted, November 2005.
10.Bansal G, Singh M, Jindal KC, Singh S. Ultraviolet-photodiode array and high-performance liquid chromatographic/ mass spectrometric studies on forced degradation behavior of glibenclamide and development of a validated stability-indicating method. J AOAC Int. 2008; 91(4): 709-719.